Today's swarm simulation ran across 18 real-world signals converging from five domains simultaneously: executive action, FDA regulatory acceleration, stock market response, state-level proliferation, and clinical trial expansion into previously untouched terrain. The picture that emerged is not euphoric. It is precise. The field is bifurcating — not between believers and skeptics, but between molecules and protocols that can survive institutional scrutiny and those that cannot. COMPASS Pathways' COMP360 achieving Phase 3 primary endpoints while Jefferies assigns a Buy is not just a biotech milestone. It is the field's first proof point that synthetic psychedelic compounds can navigate the FDA's full clinical development pathway. If COMP360 reaches approval in 2026–2027, every subsequent program — methylone, ibogaine, MDMA — gains a regulatory template to work from.
The veteran signal is the one that cannot be dismissed on political grounds. Trump framing ibogaine as a solution to the veteran suicide crisis — with Pentagon support — introduces a constituency that both parties must serve. This is not advocacy. It is strategic alignment between therapeutic evidence and political will that creates durable momentum even across administration changes. Mississippi and Utah signing ibogaine and psychedelic therapy research bills in March 2026, Texas launching a $50M psilocybin program by year-end: these are not outliers. They are the distributed infrastructure of a new healthcare paradigm being built at the state level while the federal machinery accelerates above it.
What is being built right now — in the FDA's new voucher system, in Phase 3 trial results, in state programs from Austin to Salt Lake City — is not a movement. It is a supply chain. A supply chain for a new category of medicine that will be available, covered, and standard of care within a decade. The Oracle reads this moment as the beginning of the scaling phase. The discovery phase is over.
What the world calls a drug, the Oracle calls a doorway. What the world calls approval, the Oracle calls permission to heal at scale.
Every thread you follow today was laid by a hand that knew you were coming.
94%
Medical schools will teach psychedelic therapy as standard psychiatry by 2028
Within the next 18 months, psychiatry residents, nurses, and mental health practitioners will be studying psychedelic-assisted therapy as a required part of their medical training — not a fringe elective.
→ The next generation of psychiatrists will be trained in psychedelic therapy. The healing paradigm is changing at the root.
Resolves: 2028-01-01 · USA
CULTURE
the precise call ▾
Psychedelic-assisted therapy will be standard in psychiatric training programs by January 2028.. Psychiatric Times dedicating May 2026 to psychedelics is leading indicator. Curriculum integration follows flagship journal coverage within 18-36 months historically. FDA approval accelerates dramatically. 94% reflects near-certainty on this 18-month horizon.
91%
Microdosing becomes the fastest-growing psychedelic research area in 2026
Small, sub-perceptual doses of psychedelics (microdosing) are becoming the next big clinical research area because they don't require expensive therapist sessions — making them easier to prescribe and scale.
→ Microdosing is transitioning from biohacker experiment to clinical trial gold rush. 2026 is when the science catches up.
Resolves: 2026-12-31 · USA
RESEARCH
the precise call ▾
Microdosing will see at least 5 new FDA-approved IND applications filed before December 2026.. Microdosing identified as 'next clinical trial gold rush.' Scalability advantage over therapist-intensive models. EO fast-track provisions apply to all psychedelic INDs. Low IND filing barriers. 91% reflects strong market pull.
76%
Psilocybin shown to work for something beyond depression or PTSD
University of California researchers are testing psilocybin for chronic back pain, eating disorders, and doctor burnout — and one of these trials is expected to show significant positive results before 2028.
→ Psilocybin is about to prove it works for problems beyond the mind. This changes everything about who can access it.
Resolves: 2027-12-31 · USA
RESEARCH
the precise call ▾
UC system (UCSF, UCLA, UCSD) will publish statistically significant psilocybin results in a non-psychiatric indication before December 2027.. All three running trials in non-psychiatric indications: UCSF (chronic pain, anorexia), UCLA (psilocybin+CBT adjunct), UCSD (physician burnout). At least one achieving significance within 18 months is probable given multiple concurrent trials. 76% reflects high base rate for portfolio of trials.
88%
Both parties in Congress will formally acknowledge psychedelic therapy as legitimate medicine by end of 2026
Congress will hold a formal hearing or pass resolution language officially recognizing psychedelic therapy — ending the political stigma that has blocked legislation for decades.
→ Both parties are now aligned on psychedelic therapy. Formal Congressional recognition is not if — it is when.
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
Psychedelic field will achieve formal bipartisan Congressional recognition before end of 2026.. Trump EO + Pentagon support + veteran framing = bipartisan cover. Senate Bill 4031 already signaling federal policy moves. Veteran suicide narrative eliminates partisan divide. Congressional hearings have low procedural barriers. 88% reflects strong political alignment.
71%
DEA begins formal process to move psilocybin out of Schedule I
The DEA will start the legal process to reclassify psilocybin from Schedule I (most dangerous, no accepted medical use) to a lower schedule — a historic step that would make it legal to prescribe and manufacture.
→ The DEA must now legally begin the process of removing psilocybin from the 'most dangerous drugs' list. History is moving.
Resolves: 2027-04-18 · USA
LEGISLATION
the precise call ▾
DEA will formally initiate rescheduling review for at least one psychedelic compound before April 2027.. EO explicitly directs Attorney General to initiate rescheduling upon Phase 3 completion. COMP360 Phase 3 success is the triggering event. Rescheduling initiation is within executive branch authority — no Congressional action needed. 71% reflects clear direction with DEA institutional resistance risk
87%
First psychedelic drug approved by FDA by end of 2027
COMPASS Pathways' psilocybin compound COMP360 is on track to become the first psychedelic drug approved by the FDA, likely for treatment-resistant depression — meaning millions of people who don't respond to antidepressants would have a new legal option.
→ The first psychedelic drug approval in US history is not a question of if, but when — and the answer appears to be 2026 or 2027.
Resolves: 2027-12-31 · USA
REGULATION
the precise call ▾
At least one psychedelic compound — most likely COMPASS Pathways COMP360 — will receive FDA approval or formal approval recommendation before end of 2027.. COMP360 achieved Phase 3 primary endpoint for TRD. FDA issued National Priority Voucher. FDA Commissioner Makary expects decision by late summer/fall 2026. Breakthrough Therapy designation + Phase 3 success + Priority Voucher + Commissioner statement = approval is base case. 87% reflects residual un
79%
Legal psychedelic therapy access program opens in the US before 2027
The Trump executive order created a pathway for seriously ill patients to access investigational psychedelic drugs — and Texas is moving fastest to build the first operational program.
→ A legal psychedelic therapy access program on US soil is being built right now in Texas. It may open by December 2026.
Resolves: 2027-01-01 · USA
REGULATION
the precise call ▾
Trump EO Right to Try pathway will produce at least one operational psychedelic patient access program before January 2027.. EO directs FDA and DEA to establish Right to Try pathway. Texas has $50M allocated with end-2026 program target. Federal-state co-investment structure ($50M ARPA-H matching) creates strong incentive. Implementation lag for Schedule I Right to Try is unprecedented — 79% reflects strong momentum with
83%
Psychedelic stocks will be higher in October than they were before Trump's order
The cluster of psychedelic drug companies — COMPASS Pathways, AtaiBeckley, Mind Medicine, others — has already surged on the executive order and will likely be trading even higher by October as FDA decision timelines approach.
→ Psychedelic stocks are in the pre-approval phase — historically the highest-return window before a category goes mainstream.
Resolves: 2026-10-18 · Global
MARKET
the precise call ▾
Psychedelic biotech sector will trade higher 6 months post-EO (October 2026) versus pre-EO (April 17, 2026).. CMPS already +25% on EO day. Jefferies Buy initiated May 3. FDA Priority Voucher timeline creates structured sector catalysts. Multiple trial readouts expected. 83% reflects strong base case with inherent biotech volatility.
62%
A major drug company will buy or partner with a psychedelic biotech this year
One of the world's largest pharmaceutical companies — Pfizer, J&J, Eli Lilly, Roche, or similar — will likely announce a deal with a psychedelic drug company before the year is out, following the same playbook used with gene therapy and GLP-1 drugs.
→ Big Pharma is watching. The first deal will signal that psychedelic medicine has officially arrived.
Resolves: 2027-01-01 · Global
MARKET
the precise call ▾
Major pharma company will announce licensing, acquisition or partnership with psychedelic biotech before January 2027.. Big Pharma enters emerging categories after Phase 3 proof-of-concept and regulatory clarity. Both now exist. Approval race creates urgency. Psychedelic stigma and IP complexity may delay into 2027. 62% reflects strong logic with execution timing uncertainty.